Robinhood Asset Management LLC Makes New Investment in Natera, Inc. $NTRA

Key Points

• Robinhood Asset Management acquired 41,175 Natera shares during the second quarter, valued at approximately $11.2 million. Institutional investors collectively own 99.9% of the company.
• Analysts maintain a generally bullish view, with a consensus “Moderate Buy” rating and an average price target of $319.38; individual targets range from $245 to $355.
• Natera’s latest quarterly revenue rose 37.7% year over year to $752.75 million, surpassing estimates, while its stock opened at $332.03 near its 52-week high of $333.56.

Robinhood Asset Management LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 41,175 shares of the medical research company's stock, valued at approximately $11,177,000.

Other hedge funds have also recently modified their holdings of the company. Trust Co. of Vermont acquired a new stake in shares of Natera in the 2nd quarter valued at about $26,000. Elevation Wealth Partners LLC acquired a new position in Natera during the second quarter worth approximately $30,000. Reflection Asset Management acquired a new position in Natera during the fourth quarter worth approximately $29,000. Palladiem LLC purchased a new stake in Natera in the fourth quarter valued at approximately $31,000. Finally, Bank of Jackson Hole Trust lifted its stake in Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock valued at $37,000 after buying an additional 83 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Barclays restated an "overweight" rating and set a $340.00 target price on shares of Natera in a research report on Friday, August 7th. The Goldman Sachs Group assumed coverage on shares of Natera in a research report on Friday, June 5th. They issued a "neutral" rating and a $245.00 price target for the company. Leerink Partners set a $330.00 price target on shares of Natera in a research note on Friday, August 7th. Evercore reissued an "outperform" rating and set a $300.00 price objective on shares of Natera in a research report on Monday, July 6th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $355.00 target price on shares of Natera in a report on Monday, August 10th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $319.38.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 3,076 shares of the company's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64. Following the transaction, the chief executive officer owned 99,897 shares of the company's stock, valued at $26,611,561.83. This represents a 2.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the transaction, the insider owned 129,019 shares of the company's stock, valued at $34,264,866.02. The trade was a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 181,045 shares of company stock valued at $41,330,968 in the last three months. 5.05% of the stock is owned by corporate insiders.

Natera Stock Up 2.2%

NASDAQ NTRA opened at $332.03 on Friday. The stock has a market capitalization of $47.86 billion, a P/E ratio of -244.14 and a beta of 1.51. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $333.56. The firm has a 50-day moving average price of $274.24 and a 200 day moving average price of $229.39.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.74) EPS. On average, equities research analysts expect that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source